National Yang Ming Chiao Tung University

Kaohsiung Medical University

Department of Health the Executive Yuan, Republic of China

Yun-Ming Wang

Gin-Chung Liu

Ting-Jung Chen

Chih-Wei Chiu

Yu-Jen Chen

Jinn-Moon Yang

Jui-Sheng Hsu

Hsin-Ping Lin

Chien-Hsun Lee

Wan-Chun Liu

Wen-Feng Liaw

Kai-Cheng Hsu

Chiao-Yun Chen

Wei-Hsan Chao

Kuang-Mei Hsu

Reu-Sheng Sheu

Tzu-Ying Sung

Teng-Wen Li

Shou-Cheng Wu

Shen Rong Lin

Kuei-Tang Lin

The present disclosure provides a compound for releasing nitric oxide; the compound has the structure of formula (I):  The present disclosure also provides a pharmaceutical composition containing the compound of formula (I). The present disclosure further provides a method of releasing nitric oxide, the method includes: administrating the compound of formula (I). The present disclosure also provides a method of treating disease in a patient, the method includes administrating a therapeutically effective amount of the compound of formula (I). The present disclosure also provides the method for synthesizing the compound of formula (I).

Nitric oxide releasing compound, pharmaceutical composition, use and synthesis method thereof

The present invention provides a compound of formula (I) or the salt thereof: 

Selective inhibitors for protein kinases and pharmaceutical composition and use thereof

A ligand and a metal complex having the ligand are provided. The ligand and a paramagnetic metal ion form a metal complex with high stability, high relaxivity and high biocompatibility. The metal complex of the present invention is applicable to the preparation of MRI contrast agents for detecting atherosclerosis. The MRI contrast agent includes a peptide sequence specific to a matrix metalloprotease, and can be recognized by a pathological thrombocyte to target a specific site, so as to enhance the imaging contrast.

Ligand and metal complex having the same

A cycloalkyl triamine pentacarboxylate compound coordinating to a metal ion to form a high stability metal complex in serum is provided. The metal complex of the present invention can be used as a contrast agent for magnetic resonance imaging (MRI).

Cycloalkyl triamine pentacarboxylate as ligands for paramagnetic metal complexes

A ligand of Formula (I) is provided: wherein Arepresents a hydrogen atom, a nitro group, an amino group, a thiocyanato group, or &#x2014;Z&#x2014;Y, in which Z is a divalent linking group and Y is a group derived from a biocompatible molecule, with the proviso that when X is methylene, Acannot be a hydrogen atom or a nitro group. A metal complex having the ligand is also provided and is useful as a blood pool contrast agent or a targeting contrast agent.

Ligand and metal complex

A nanoparticle contains a core including superparamagnetic nanoparticles and having an outer surface, and siloxanyl moieties covalently coupled to the outer surface of the core and having Formula (I): In formula (I): Xand Xindependently represent methylene, ethylene or propylene; R represents an optionally substituted pyridyl group, or &#x2014;S&#x2014;R is a group derived from a targeting ligand containing &#x2014;SH group and effective to bind specifically with a predetermined targeted cell in an object; n and m independently represent an integer ranging from 1 to 3; and p represents an integer ranging from 9 to 45. The nanoparticles are suitable for use as a magnetic resonance imaging contrast agent.

Nanoparticle and magnetic resonance imaging contrast agent

The present invention provides the synthetic method and superparamagnetic iron oxide nanoparticles capable of targeting to the folic acid receptors existing on the cell membranes and with high relaxivity. The iron oxide nanoparticles of the present invention can further be used as the contrast agents for magnetic resonance imaging (MRI).

Folate-receptor-targeting iron oxide nanoparticles coated with poly(ethylene glycol)

This invention provides a novel probe, which contains a prostate peptide substrate. The probe can be used as a prostate diagnostic agent for optical imaging. An 11 amino acid peptide substrate is synthesized for specific prostate-specific antigen (PSA). This protected graft copolymer (PGC) consists of a poly-L-lysine (PL) backbone and methoxypoly(ethylene glycol) (MPEG). Two terminals of peptide substrate are bound to poly-L-lysine and Cy5.5 fluorochrome. This probe will be used as a NIR (near-infrared fluorescence) probe for optical imaging.

Prostate-specific antigen probes for optical imaging

The present invention provides a triaminepentaacetic acid compound which can be used as a ligand to coordinate to a metal ion to form a paramagnetic metal complex. The paramagnetic metal complex of the present invention can be used as a contrast agent for magnetic resonance imaging (MRI).

Growing community of inventors

Kaohsiung, Taiwan

Yun-Ming Wang